In this episode, Jennifer Cocohoba, PharmD, AAHIVP, and David Koren, PharmD, MPH, AAHIVP, FIDSA, cover the most impactful LA ART and LA PrEP clinical studies presented at AIDS 2024, including:The PURPOSE 1 study of twice-yearly lenacapavir injections vs daily oral tenofovir as PrEP in cisgender womenAn open-label extension of HPTN 084 evaluating LA CAB safety during pregnancy48-week data from the IMPAACT 2017/MOCHA study of LA CAB + RPV in adolescents with HIVA substudy of FLAIR evaluating the efficacy, safety, and tolerability of SC self-administration of LA CAB + RPV Presenters:Jennifer Cocohoba, PharmD, AAHIVPProfessor of Clinical PharmacyDepartment of Clinical PharmacyUniversity of California San Francisco School of PharmacySan Francisco, CaliforniaDavid Koren, PharmD, MPH, AAHIVP, FIDSAAdjunct Clinical ProfessorTemple University School of PharmacyClinical Pharmacist SpecialistTemple University Health SystemPhiladelphia, PennsylvaniaTo access all of our new podcast episodes, subscribe to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.  See the full program here. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related